Schmidt N, Büttner N, Thimme R
Abteilung Innere Medizin II, Universitätsklinikum Freiburg, Freiburg.
Dtsch Med Wochenschr. 2013 Apr;138(14):740-4. doi: 10.1055/s-0032-1333030. Epub 2013 Mar 26.
Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide with a high mortality. Available therapeutical options are limited, thus the development of new, innovative therapeutic strategies is crucial. Based on the immune system's antitumoral effect, immunotherapy is a promising new treatment option. Specific antitumoral T-cell responses can be detected in patients with HCC, however, their impact on tumor control seems to be rather weak. Various different immunosuppressive mechanisms seem to contribute to the failure of tumor-specific T-cell responses. Thus, the aim of immunotherapeutic strategies is to address these mechanisms of T-cell failure and to induce new or to boost existing antitumoral immune responses.
肝细胞癌（HCC）是全球第五大常见肿瘤，死亡率很高。现有的治疗选择有限，因此开发新的、创新的治疗策略至关重要。基于免疫系统的抗肿瘤作用，免疫疗法是一种有前景的新治疗选择。在HCC患者中可以检测到特异性抗肿瘤T细胞反应，然而，它们对肿瘤控制的影响似乎相当微弱。各种不同的免疫抑制机制似乎导致了肿瘤特异性T细胞反应的失败。因此，免疫治疗策略的目的是解决T细胞功能衰竭的这些机制，并诱导新的或增强现有的抗肿瘤免疫反应。
